228 related articles for article (PubMed ID: 15479647)
1. Unstable plasma thalidomide concentration in patients with refractory multiple myeloma.
Kodama T; Horiuchi R; Tsukamoto N; Nojima Y; Murakami H
Lab Hematol; 2004; 10(3):132-6. PubMed ID: 15479647
[TBL] [Abstract][Full Text] [Related]
2. [Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%].
Wu KL; Schaafsma MR; Lokhorst HM; Wijermans PW; van der Holt B; Sonneveld P
Ned Tijdschr Geneeskd; 2002 Aug; 146(31):1445-8. PubMed ID: 12190011
[TBL] [Abstract][Full Text] [Related]
3. Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma.
Ciepłuch H; Baran W; Hellmann A
Med Sci Monit; 2002 Apr; 8(4):PI31-6. PubMed ID: 11951079
[TBL] [Abstract][Full Text] [Related]
4. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
[TBL] [Abstract][Full Text] [Related]
5. [Thalidomide treatment of patients with refractory myeloma in the institutes participating in the Japan Myeloma Study Group].
Murakami H; Handa H; Imai K; Kanakura Y; Kosaka M; Sawamura M; Shimazaki C; Suzuki K; Ishii A; Takagi T; Taniwaki M; Togawa A; Hata H; Wakayama T; Takatsuki K;
Rinsho Ketsueki; 2004 Jun; 45(6):468-72. PubMed ID: 15287523
[TBL] [Abstract][Full Text] [Related]
6. A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma.
Kodama T; Abe M; Iida S; Ozaki S; Sakai A; Sawamura M; Shimazaki C; Miyata A; Wakayama T; Murakami H
Clin Lymphoma Myeloma; 2009 Apr; 9(2):154-9. PubMed ID: 19406727
[TBL] [Abstract][Full Text] [Related]
7. [Low-dose thalidomide in refractory and relapsing multiple myeloma].
Radocha J; Maisnar V
Vnitr Lek; 2007 Feb; 53(2):129-34. PubMed ID: 17419173
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of thalidomide in refractory multiple myeloma.
Singhal S; Mehta J; Desikan R; Ayers D; Roberson P; Eddlemon P; Munshi N; Anaissie E; Wilson C; Dhodapkar M; Zeddis J; Barlogie B
N Engl J Med; 1999 Nov; 341(21):1565-71. PubMed ID: 10564685
[TBL] [Abstract][Full Text] [Related]
9. [Thalidomide therapy in patients with refractory or relapsed multiple myeloma].
Ochiai N; Shimazaki C; Uchida R; Fuchida S; Okano A; Ashihara E; Inaba T; Fujita N; Adachi Y; Nishio A; Nakagawa M
Rinsho Ketsueki; 2002 Dec; 43(12):1045-9. PubMed ID: 12607993
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide treatment of resistant or relapsed multiple myeloma patients.
Hus M; Dmoszynska A; Soroka-Wojtaszko M; Jawniak D; Legiec W; Ciepnuch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Manko J;
Haematologica; 2001 Apr; 86(4):404-8. PubMed ID: 11325647
[TBL] [Abstract][Full Text] [Related]
11. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring.
Mileshkin L; Stark R; Day B; Seymour JF; Zeldis JB; Prince HM
J Clin Oncol; 2006 Sep; 24(27):4507-14. PubMed ID: 16940275
[TBL] [Abstract][Full Text] [Related]
12. Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.
Zemanova M; Scudla V; Adam Z; Gregora E; Pour L; Minarik J; Pavlicek P; Pika T; Bacovsky J
Neoplasma; 2008; 55(4):345-9. PubMed ID: 18505347
[TBL] [Abstract][Full Text] [Related]
13. Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma.
Huang SY; Tang JL; Yao M; Ko BS; Hong RL; Tsai W; Wang CH; Tien HF; Shen MC; Chen YC
Ann Hematol; 2003 Sep; 82(9):558-64. PubMed ID: 12898185
[TBL] [Abstract][Full Text] [Related]
14. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
15. Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma.
Murakami H; Handa H; Abe M; Iida S; Ishii A; Ishikawa T; Ishida T; Oota M; Ozaki S; Kosaka M; Sakai A; Sawamura M; Shimazaki C; Shimizu K; Takagi T; Hata H; Fukuhara T; Fujii H; Miyata A; Wakayama T; Takatsuki K
Eur J Haematol; 2007 Sep; 79(3):234-9. PubMed ID: 17655699
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism].
Wang M; Liu Y; Li Y; Wu H
Zhonghua Xue Ye Xue Za Zhi; 2002 Oct; 23(10):514-6. PubMed ID: 12482346
[TBL] [Abstract][Full Text] [Related]
17. Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.
Schütt P; Ebeling P; Buttkereit U; Brandhorst D; Opalka B; Hoiczyk M; Flasshove M; Hense J; Bojko P; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2005 Jan; 74(1):40-6. PubMed ID: 15613105
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
[TBL] [Abstract][Full Text] [Related]
19. Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Pönisch W; Rozanski M; Goldschmidt H; Hoffmann FA; Boldt T; Schwarzer A; Ritter U; Rohrberg R; Schwalbe E; Uhlig J; Zehrfeld T; Schirmer V; Haas A; Kreibich U; Niederwieser D;
Br J Haematol; 2008 Oct; 143(2):191-200. PubMed ID: 18752593
[TBL] [Abstract][Full Text] [Related]
20. [Single-agent thalidomide for advanced and refractory multiple myeloma].
Okikawa Y; Takimoto Y; Noda M; Imagawa J; Katayama Y; Sakai A; Okita H; Fujimura K; Kimura A
Rinsho Ketsueki; 2003 Jun; 44(6):368-74. PubMed ID: 12884814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
